Becton, Dickinson & Aktie News

Dividend Aristocrats rebounded in June and are now outperforming SPY YTD with a 9.61% return versus SPY's 6.91%. CAT leads 2026 performance at +76.98%, with 46 Aristocrats now ahead of SPY and 39 posting double-digit total returns. Recent dividend increases averaged 4.09%, slightly below the 2025 average, with 2026's average dividend growth rate at 3.97%.

Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innov...

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures. FRANKLIN LAKES, N.J.

With a new presidential administration set to take office on Jan. 20, 2025, some investors may be uncertain about how new policies and personnel will affect the stock market and interest rates. Will tariffs, discarded trade deals, and frayed alliances help or hurt the market?

FRANKLIN LAKES, N.J., May 18, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1.

Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript